CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin
The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever Phase I in pediatric patientsFDA modified the trial design to designate overall survival as the trial’s primary endpointThe market for brain tumor therapies is expected to grow at a CAGR of 10% and reach an estimated $1.6 billion in 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a…